BIOMAT Database Logo BIOMAT Database Logo

In vitro and in vivo antifungal activities of liposomal amphotericin B, and amphotericin B lipid complex. 1994

K Mitsutake, and S Kohno, and Y Miyazaki, and T Noda, and H Miyazaki, and T Miyazaki, and M Kaku, and H Koga, and K Hara
Second Department of Internal Medicine, Nagasaki University School of Medicine, Japan.

The in vitro and in vivo antifungal activities of liposomal amphotericin B (L-AMPH) and amphotericin B lipid complex (ABLC), which is composed of amphotericin B and the phospholipids dimyristoyl phosphatidylcholine and dimyristoyl phosphatidylglycerol, were compared with those of conventional amphotericin B (Fungizone, AMPH). The acute intravenous toxicity was markedly lower in BALB/c mice; 50% lethal doses (LD50s) were 2.75 mg/kg in AMPH, 32.9 mg/kg in L-AMPH and > 75 mg/kg in ABLC. In vitro antifungal activities against Candida albicans, C. parapsilosis, C. tropicalis, C. glabrata, and C. krusei were evaluated by the agar plate dilution method. The activities were unchanged against C. albicans, but MICs increased more than four fold in 18 of the 20 strains other than C. albicans in L-AMPH and in 9 of the 20 in ABLC. L-AMPH and ABLC were as efficacious as AMPH in the treatment of mice infected with C. albicans, and at a dose of 0.5 and 1.0 mg/kg of body weight, ABLC was more efficacious on survival A ten-times larger dose (10 mg/kg) of L-AMPH and ABLC was administered to mice with 100% survival, suggesting improved tolerability as compared to amphotericin B.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007928 Lethal Dose 50 The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population. LD50,Dose 50, Lethal
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D010743 Phospholipids Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system. Phosphatides,Phospholipid
D002175 Candida A genus of yeast-like mitosporic Saccharomycetales fungi characterized by producing yeast cells, mycelia, pseudomycelia, and blastophores. It is commonly part of the normal flora of the skin, mouth, intestinal tract, and vagina, but can cause a variety of infections, including CANDIDIASIS; ONYCHOMYCOSIS; VULVOVAGINAL CANDIDIASIS; and CANDIDIASIS, ORAL (THRUSH). Candida guilliermondii var. nitratophila,Candida utilis,Cyberlindnera jadinii,Hansenula jadinii,Lindnera jadinii,Monilia,Pichia jadinii,Saccharomyces jadinii,Torula utilis,Torulopsis utilis,Monilias
D002176 Candida albicans A unicellular budding fungus which is the principal pathogenic species causing CANDIDIASIS (moniliasis). Candida albicans var. stellatoidea,Candida stellatoidea,Dematium albicans,Monilia albicans,Myceloblastanon albicans,Mycotorula albicans,Parasaccharomyces albicans,Procandida albicans,Procandida stellatoidea,Saccharomyces albicans,Syringospora albicans

Related Publications

K Mitsutake, and S Kohno, and Y Miyazaki, and T Noda, and H Miyazaki, and T Miyazaki, and M Kaku, and H Koga, and K Hara
In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole.
September 1999, The Journal of antimicrobial chemotherapy,
K Mitsutake, and S Kohno, and Y Miyazaki, and T Noda, and H Miyazaki, and T Miyazaki, and M Kaku, and H Koga, and K Hara
Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole.
January 2000, Chemotherapy,
K Mitsutake, and S Kohno, and Y Miyazaki, and T Noda, and H Miyazaki, and T Miyazaki, and M Kaku, and H Koga, and K Hara
In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important?
April 1998, Antimicrobial agents and chemotherapy,
K Mitsutake, and S Kohno, and Y Miyazaki, and T Noda, and H Miyazaki, and T Miyazaki, and M Kaku, and H Koga, and K Hara
In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B.
March 1984, Antimicrobial agents and chemotherapy,
K Mitsutake, and S Kohno, and Y Miyazaki, and T Noda, and H Miyazaki, and T Miyazaki, and M Kaku, and H Koga, and K Hara
Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.
May 2015, Antimicrobial agents and chemotherapy,
K Mitsutake, and S Kohno, and Y Miyazaki, and T Noda, and H Miyazaki, and T Miyazaki, and M Kaku, and H Koga, and K Hara
Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis.
August 2010, Antimicrobial agents and chemotherapy,
K Mitsutake, and S Kohno, and Y Miyazaki, and T Noda, and H Miyazaki, and T Miyazaki, and M Kaku, and H Koga, and K Hara
In vitro activities of amphotericin B deoxycholate and liposomal amphotericin B against 604 clinical yeast isolates.
December 2014, Journal of medical microbiology,
K Mitsutake, and S Kohno, and Y Miyazaki, and T Noda, and H Miyazaki, and T Miyazaki, and M Kaku, and H Koga, and K Hara
[Visceral leishmaniasis associated with Wegener disease. Use of lipid complex amphotericin B and liposomal amphotericin B].
May 1999, Presse medicale (Paris, France : 1983),
K Mitsutake, and S Kohno, and Y Miyazaki, and T Noda, and H Miyazaki, and T Miyazaki, and M Kaku, and H Koga, and K Hara
Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
July 2013, Diagnostic microbiology and infectious disease,
K Mitsutake, and S Kohno, and Y Miyazaki, and T Noda, and H Miyazaki, and T Miyazaki, and M Kaku, and H Koga, and K Hara
Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.
January 2004, PharmacoEconomics,
Copied contents to your clipboard!